SCHEMBL1480852

SCHEMBL1480852

CCCn1cc(-c2ccc(Cl)cc2Cl)nc1C=Cc1ccc(-c2ccc(OC)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 3/20 0.42
DPP8 Q6V1X1 2/20 0.42
DPP9 Q86TI2 2/20 0.42
GRM2 Q14416 1/20 0.41
MAPT P10636 4/20 0.39
ALDH1A1 P00352 3/20 0.39
LMNA P02545 3/20 0.39
RELA Q04206 1/20 0.39
CXCR2 P25025 1/20 0.38
AHR P35869 1/20 0.38
TLR8 Q9NR97 1/20 0.38
GABRA2 P47869 1/20 0.38
GABRB2 P47870 1/20 0.38
NLRP3 Q96P20 1/20 0.37
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
PKM P14618 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1480849 1.00 DPP4 (0.42) DPP4DPP8DPP9GRM2MAPT
SCHEMBL1481899 0.94 TLR8 (0.43) DPP4DPP8DPP9MAPTALDH1A1
SCHEMBL1481901 0.94 TLR8 (0.43) DPP4DPP8DPP9MAPTALDH1A1
SCHEMBL1480187 0.92 DPP4 (0.43) DPP4DPP8DPP9MAPTALDH1A1
SCHEMBL1480190 0.92 DPP4 (0.43) DPP4DPP8DPP9MAPTALDH1A1
SCHEMBL1481741 0.91 TLR8 (0.43) DPP4DPP8DPP9MAPTALDH1A1
SCHEMBL1481743 0.91 TLR8 (0.43) DPP4DPP8DPP9MAPTALDH1A1
SCHEMBL1480782 0.89 RELA (0.42) DPP4DPP8DPP9MAPTALDH1A1
SCHEMBL1480780 0.89 RELA (0.42) DPP4DPP8DPP9MAPTALDH1A1
SCHEMBL1480748 0.87 DPP4 (0.41) DPP4DPP8DPP9MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
EP-1594847-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS Transtech Pharma, Inc. (US) 2005-11-16 EP disclosed
WO-2004071447-A9 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC (US) 2005-10-13 WO disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed
WO-2004071447-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC. (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ DPP4 132/4885DPP8 144/4885DPP9 113/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ DPP4 132/4885DPP8 144/4885DPP9 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.